Table 2.

Cost-effectiveness analysis results using institutional costs and AWP

Institutional costAWP
Primary base-case analysisPSASecondary base-case analysisPSA
DrugCost, $AEACost, $AEACost, $AEACost, $AEA
Argatroban 1250 0.9957 1186 0.9957 3081 0.9957 3017 0.9958 
Bivalirudin 1466 0.9947 1400 0.9947 2187 0.9947 2121 0.9948 
Fondaparinux 151 0.9989 151 0.9989 555 0.9989 555 0.9989 
Institutional costAWP
Primary base-case analysisPSASecondary base-case analysisPSA
DrugCost, $AEACost, $AEACost, $AEACost, $AEA
Argatroban 1250 0.9957 1186 0.9957 3081 0.9957 3017 0.9958 
Bivalirudin 1466 0.9947 1400 0.9947 2187 0.9947 2121 0.9948 
Fondaparinux 151 0.9989 151 0.9989 555 0.9989 555 0.9989 

AEA, adverse event averted.

or Create an Account

Close Modal
Close Modal